Soligenix (SNGX) Q2 2024 earnings summary

Executive summary

• Soligenix is a late-stage biopharmaceutical company focused on rare diseases, advancing HyBryte™ for CTCL with a second Phase 3 trial set to begin enrollment by end of 2024 and top-line results expected in H2 2026.

• Other pipeline programs include SGX302 for psoriasis, SGX942/SGX945 for inflammatory diseases, and multiple vaccine candidates supported by government grants.

• Preparing a Phase 2 study for SGX945 in Behçet's disease and expecting top-line results for both this and the ongoing SGX302 psoriasis study in H1 2025.

• Completed a reverse stock split (1-for-16) in June 2024 and raised $4.75M in an April 2024 public offering, with an additional $4.2M from warrant exercises in July 2024.

• Actively exploring partnership, M&A opportunities, and strategic initiatives to create long-term shareholder value.

Financial highlights

• Net loss for Q2 2024 was $1.64M, or $(1.31) per share, with revenues of $2,342, down 99% from Q2 2023 due to the end of higher-margin grants.

• Cash and cash equivalents as of June 30, 2024 were $9.41M, up from $8.45M at year-end 2023, excluding $4.1M in net proceeds from recent warrant exercises.

• Research and development expenses for Q2 2024 were $501K, down 34% year-over-year, mainly due to clinical trial accrual adjustments.

• General and administrative expenses rose to $1.24M, up 40% year-over-year, driven by legal and professional fees.

• Working capital as of June 30, 2024 was $3.31M, a slight decrease from $3.36M at December 31, 2023.

Outlook and guidance

• Management believes current resources support operations through Q2 2025, but not for 12 months beyond the financial statement issuance date, raising substantial doubt about going concern.

• Plans to secure additional capital via equity/debt offerings, strategic transactions, and government grants, but no commitments are in place.

• Research and development expenditures for the next 12 months are expected to be $6.4M, with anticipated contract/grant reimbursements of $0.2M.

• Second Phase 3 HyBryte trial in CTCL to begin soon, with regulatory approvals sought upon successful completion.

• Continued focus on resource allocation and strategic initiatives to support long-term growth.